Literature DB >> 15080923

Synthesis and biological activities of some new dibenzopyranones and dibenzopyrans: search for potential oestrogen receptor agonists and antagonists.

Jaya Pandey1, Ashok K Jha, K Hajela.   

Abstract

Continuing our search for newer oestrogen agonists or antagonists and extending our work on the exploration of benzopyran related compounds, some new tricyclic molecules bridged between the active molecules of 3,4-diaryl chroman and 2,3-diaryl benzopyrans have been synthesised. Structural modifications at different positions with elements known to impart agonist or antagonist activities have been carried out to prepare the desired molecules. The target compounds were screened for their anti-osteoporotic (agonist) and anti-uterotrophic (antagonist) activities and were found to be moderately active.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15080923     DOI: 10.1016/j.bmc.2004.02.018

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  3 in total

1.  Novel Regioselective Synthesis of Urolithin Glucuronides─Human Gut Microbiota Cometabolites of Ellagitannins and Ellagic Acid.

Authors:  Jose M Villalgordo; Laura Trulli; Rocío García-Villalba; Victor García; Yusuf Althobaiti; Francisco A Tomás-Barberán
Journal:  J Agric Food Chem       Date:  2022-05-09       Impact factor: 5.895

2.  Urolithin and Reduced Urolithin Derivatives as Potent Inhibitors of Tyrosinase and Melanogenesis: Importance of the 4-Substituted Resorcinol Moiety.

Authors:  Sanggwon Lee; Heejeong Choi; Yujin Park; Hee Jin Jung; Sultan Ullah; Inkyu Choi; Dongwan Kang; Chaeun Park; Il Young Ryu; Yeongmu Jeong; YeJi Hwang; Sojeong Hong; Pusoon Chun; Hyung Ryong Moon
Journal:  Int J Mol Sci       Date:  2021-05-25       Impact factor: 5.923

3.  3,4-Di-hydro-1H-benzo[c]chromene-1,6(2H)-dione.

Authors:  Liang-Yan Cui; Yan He; Xue-Sen Fan
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2013-04-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.